Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Dec;24(6):827–829. doi: 10.1111/j.1365-2125.1987.tb03254.x

Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.

P A Philip 1, C A James 1, H J Rogers 1
PMCID: PMC1386412  PMID: 3440103

Abstract

The possibility of simplifying the regimen for the collection of urine samples in the determination of the debrisoquine metabolic ratio (DMR) was explored in 15 normal subjects. In the extensive metaboliser subgroup (EM; n = 11), there was a close correlation between the DMR as determined by an 8 h urine collection and the debrisoquine/4-hydroxydebrisoquine ratio (D/4-OHD) in the hourly samples (excluding the first hour). In the poor metabolisers (PM; n = 4) the phenotype could be identified, but it was not possible to estimate the DMR reliably.

Full text

PDF
827

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature. 1984 Nov 8;312(5990):169–170. doi: 10.1038/312169a0. [DOI] [PubMed] [Google Scholar]
  2. Baer A. N., McAllister C. B., Wilkinson G. R., Woosley R. L., Pincus T. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum. 1986 Jul;29(7):843–850. doi: 10.1002/art.1780290705. [DOI] [PubMed] [Google Scholar]
  3. Barbeau A., Cloutier T., Roy M., Plasse L., Paris S., Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet. 1985 Nov 30;2(8466):1213–1216. doi: 10.1016/s0140-6736(85)90743-3. [DOI] [PubMed] [Google Scholar]
  4. Clark D. W. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs. 1985 Apr;29(4):342–375. doi: 10.2165/00003495-198529040-00003. [DOI] [PubMed] [Google Scholar]
  5. Davies D. S., Kahn G. C., Murray S., Brodie M. J., Boobis A. R. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol. 1981 Jan;11(1):89–91. doi: 10.1111/j.1365-2125.1981.tb01108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
  7. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Idle J. R., Mahgoub A., Sloan T. P., Smith R. L., Mbanefo C. O., Bababunmi E. A. Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer. Cancer Lett. 1981 Feb;11(4):331–338. doi: 10.1016/0304-3835(81)90099-9. [DOI] [PubMed] [Google Scholar]
  9. Jackson P. R., Tucker G. T., Lennard M. S., Woods H. F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol. 1986 Nov;22(5):541–550. doi: 10.1111/j.1365-2125.1986.tb02933.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kalow W. Genetic variation in the human hepatic cytochrome P-450 system. Eur J Clin Pharmacol. 1987;31(6):633–641. doi: 10.1007/BF00541288. [DOI] [PubMed] [Google Scholar]
  11. Lennard M. S., Silas J. H., Smith A. J., Tucker G. T. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr. 1977 Mar 11;133(1):161–166. doi: 10.1016/s0021-9673(00)89216-x. [DOI] [PubMed] [Google Scholar]
  12. Lennard M. S., Tucker G. T., Woods H. F. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1986 Jan-Feb;11(1):1–17. doi: 10.2165/00003088-198611010-00001. [DOI] [PubMed] [Google Scholar]
  13. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  14. Peart G. F., Boutagy J., Shenfield G. M. Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol. 1986 May;21(5):465–471. doi: 10.1111/j.1365-2125.1986.tb02827.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rawlins M. D. Pharmocogenetic implications of polymorphic debrisoquine hydroxylations. Q J Med. 1985 Feb;54(214):115–116. [PubMed] [Google Scholar]
  16. Silas J. H., Lennard M. S., Tucker G. T., Smith A. J., Malcolm S. L., Marten T. R. Why hypertensive patients vary in their response to oral debrisoquine. Br Med J. 1977 Feb 12;1(6058):422–425. doi: 10.1136/bmj.1.6058.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sloan T. P., Lancaster R., Shah R. R., Idle J. R., Smith R. L. Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol. 1983 Apr;15(4):443–450. doi: 10.1111/j.1365-2125.1983.tb01528.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES